BRD4 and cancer: To determine if OPT-0139–cisplatin combination treatment alters the expression level of BRD4, hypoxia signaling, angiogenesis, cancer stemness, and apoptosis marker genes, total RNA was isolated from the control, OPT-0139, cisplatin, OPT-0139/cisplatin-injected mouse tumor, and then analyzed by semi-quantitative real-time PCR.